Whether this is unique to prostate cancer has yet to be determined, and it may be possible that serum levels decrease in a variety of cancer types and, thus, HAVcR-1 may need to be used in conjunction with other biomarkers such as PSA in the instance of prostate cancer or followed by further testing to determine the cancer type. Here, HAVCR1 is linked to prostate cancer.